Manulife Financial is one of the Big Three Canadian life insurers... Show more
Manulife Financial Corporation has traded with unusual calm over the past month. After hovering near the low-$40s in late September, shares recovered to the mid-$40s, leaving the stock effectively unchanged on a 30-day basis. This stability stands out against a broader financials sector that has periodically reacted to shifting interest-rate expectations and equity-market volatility.
As one of North America's largest insurers and a major player in Asian life insurance, Manulife is often viewed by investors as a defensive, income-generating holding. Its diversified earnings base helps cushion the company against weakness in any single geography or business line, a trait that has contributed to relatively low share-price volatility in recent weeks.
Headquartered in Toronto, Manulife Financial Corporation is an international financial services provider operating as Manulife across Canada and Asia and primarily as John Hancock in the United States. Its business is organized across insurance and annuity segments in Asia, Canada, and the U.S., alongside a Global Wealth and Asset Management (Global WAM) business branded Manulife Investment Management.
The company serves millions of customers across roughly 25 markets, with assets under management and administration exceeding US$1 trillion. Its wealth platform spans retail, retirement, and institutional clients, including the Manulife Comvest private credit franchise and Manulife | CQS. Competitive strengths include scale in Asian distribution, a well-known U.S. brand in John Hancock, and a capital base that supports consistent shareholder returns through dividends and buybacks.
Manulife reported second-quarter 2026 results in early August, highlighted by a double-digit year-over-year increase in core earnings and a 21% rise in Asia core earnings, reflecting continued business growth across the region. Asia has been the company's most dynamic segment, with strength in Hong Kong, Japan, and Singapore contributing to higher annualized premium equivalent sales and new business value.
Beyond earnings, Manulife has made notable strategic moves. The company completed the acquisition of PT Schroder Investment Management Indonesia, reinforcing its position as the largest asset manager in Indonesia, and entered a strategic partnership with Legal & General to expand distribution and product capabilities, particularly across Europe. These steps broaden the company's wealth-management footprint and diversify its growth avenues.
Artificial intelligence has also become a recurring theme. Manulife was named the number one life insurer for AI maturity for the second consecutive year in the 2026 Evident AI Index for Insurance, and it continues to roll out AI-powered tools across underwriting, claims, and distributor support. These initiatives are aimed at improving efficiency and customer experience rather than generating direct near-term revenue.
For investors looking to supplement traditional research with data-driven tools, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, timeframe, and performance metrics, allowing users to explore approaches ranging from short-term momentum to longer-horizon trend-following. The page is designed as a discovery tool, helping traders evaluate automated strategies that align with their own goals and risk tolerance.
Looking ahead, Manulife's trajectory will likely hinge on several factors. Sustained growth in Asia, particularly in Hong Kong and mainland China, remains central to the company's earnings expansion, while the Global WAM business will be closely watched for signs that net flows stabilize after a period of retail and retirement outflows in North America.
Macroeconomic conditions also matter. Interest-rate levels, equity-market performance, and currency movements influence both investment spreads and fee income. Investors should monitor the company's progress toward its medium-term targets, including 18%+ core return on equity by 2027 and continued capital returns through dividends and buybacks. Regulatory developments across its operating regions and the ongoing eMPF transition in Hong Kong represent additional variables worth tracking.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Moving Average Convergence Divergence (MACD) for MFC turned positive on October 15, 2026. Looking at past instances where MFC's MACD turned positive, the stock continued to rise in 31 of 46 cases over the following month. The odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on MFC as a result. In 49 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
MFC moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MFC crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +2.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where MFC advanced for three days, in 223 of 350 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 197 of 354 cases where MFC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
The 10-day RSI Indicator for MFC moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 23 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 51%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MFC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.
MFC broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. MFC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.574) is normal, around the industry mean (1.310). P/E Ratio (11.962) is within average values for comparable stocks, (19.517). Projected Growth (PEG Ratio) (0.876) is also within normal values, averaging (0.463). Dividend Yield (0.032) settles around the average of (0.047) among similar stocks. P/S Ratio (1.780) is also within normal values, averaging (1.303).
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of life and health insurance and reinsurance services
Industry LifeHealthInsurance